News

Castor Catalyst, Castor’s AI-driven clinical data platform, reads data directly from source records and proposes each value for a human reviewer to confirm. In a recent study for a Top-10 BioPharma sponsor, reviewers accepted 99.16 percent of the values Catalyst extracted and overrode just 0.78 percent, submitting 14,282 values to the clinical database with no upload errors. Catalyst is now live in production across five countries, in studies spanning real-world evidence, post-market clinical follow-up, and pivotal medical device trials. It runs on a Google Gemini model with United States and European Union data residency, zero data retention, and mandatory human review of every field.

Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform update.

Castor joins the Critical Path Institute (C-Path) eCOA Consortium, bringing insights from 300+ industry studies to advance participant-centric data standards.

Castor has launched Castor Catalyst, an innovative AI-powered platform developed in collaboration with Google Cloud. Built on Google’s Gemini models and Vertex AI, Catalyst is pioneering the concept of “self-driving clinical trials”. This solution automates the most burdensome and repetitive tasks in clinical research, addressing bottlenecks in the life sciences industry. By creating human-supervised, automated workflows, Castor aims to achieve a 50% reduction in manual effort in Phase 2/3 studies, drastically cutting costs, time, and errors, and accelerating the generation of regulatory-grade Real-World Evidence (RWE).

OTP login is now standard in Castor’s eConsent platform. No account setup or passwords to create. Participants receive a one-time code, enter it, and move straight into the study flow—landing page, screener, consent. The result: >98% screener completion in a recent real-world study. Castor doesn’t treat login as an afterthought. This is built-in, not bolted on. If your platform still relies on email links and account creation, you’re losing participants before the study even starts.

Castor and LLS launch a study using AI and remote blood sampling to improve care for patients with leukemia and lymphoma.

Castor has announced free access to its clinical trial technology platform for U.S. researchers impacted by recent NIH funding cuts. Through the Castor for Impact Program, investigators can maintain data integrity, streamline workflows, and keep projects moving forward, despite reduced indirect cost allocations threatening vital scientific progress and ongoing discovery.

Innovative Program Offers Discounted or Free Access to Clinical Trial Technology, Empowering Underserved Research Areas and Early-Stage Biotech and Medical Device Companies

The partnership will streamline the synchronization of clinical trial and real-world data throughout the clinical research stages.